BACKGROUND: The HER-2 neu (c-erbB-2) oncogene product p185neu is expressed by most ovarian cancers and overexpressed in approximately 30%. METHODS: Sera from patients with ovarian cancer were evaluated for neu antigen using an enzyme-linked immunoassay and for CA 125 antigen by radioimmunoassay. Tissue levels of neu from the same patients were determined by immunohistochemical staining with anti-neu monoclonal antibody. RESULTS: Elevated levels (> 2050 human neu unit [HNU]/ml) of circulating neu determinants have been detected in sera from 15% of 48 patients. Of 45 patients for whom tumor tissue had been cryopreserved, overexpression of neu was found in 17 by immunohistochemical analysis; of these 17, serum neu levels were elevated in 5 (29%). Among the 28 patients with normal to moderate tissue expression of neu, only 2 (7%) had elevated serum neu levels. Thus, elevated serum neu levels predicted tissue overexpression with a specificity of 93%. Serum neu levels were not related to serum levels of CA 125. CONCLUSION: Serum and tissue levels of neu correlate in patients with epithelial ovarian cancer.
BACKGROUND: The HER-2 neu (c-erbB-2) oncogene product p185neu is expressed by most ovarian cancers and overexpressed in approximately 30%. METHODS: Sera from patients with ovarian cancer were evaluated for neu antigen using an enzyme-linked immunoassay and for CA 125 antigen by radioimmunoassay. Tissue levels of neu from the same patients were determined by immunohistochemical staining with anti-neu monoclonal antibody. RESULTS: Elevated levels (> 2050 humanneu unit [HNU]/ml) of circulating neu determinants have been detected in sera from 15% of 48 patients. Of 45 patients for whom tumor tissue had been cryopreserved, overexpression of neu was found in 17 by immunohistochemical analysis; of these 17, serum neu levels were elevated in 5 (29%). Among the 28 patients with normal to moderate tissue expression of neu, only 2 (7%) had elevated serum neu levels. Thus, elevated serum neu levels predicted tissue overexpression with a specificity of 93%. Serum neu levels were not related to serum levels of CA 125. CONCLUSION: Serum and tissue levels of neu correlate in patients with epithelial ovarian cancer.
Authors: Dong Il Park; Mun Su Kang; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Won Kon Han; Hungdai Kim; Seung Ho Ryu; Antonia R Sepulveda Journal: Int J Colorectal Dis Date: 2006-09-01 Impact factor: 2.571
Authors: Samuel D Bernal; Enrique T Ona; Aileen Riego-Javier; Romulo DE Villa; Gloria R Cristal-Luna; Josephine B Laguatan; Eunice R Batac; Oscar Q Canlas Journal: Oncol Lett Date: 2011-09-20 Impact factor: 2.967
Authors: Dong Il Park; Jung Won Yun; Jung Ho Park; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Chang Hak Yoo; Byung Ho Son; Eun Yoon Cho; Seoung Wan Chae; Eo-Jin Kim; Jin Hee Sohn; Seung Ho Ryu; Antonia R Sepulveda Journal: Dig Dis Sci Date: 2006-07-26 Impact factor: 3.199
Authors: Isabelle J Létourneau; Michael C J Quinn; Lu-Lin Wang; Lise Portelance; Katia Y Caceres; Louis Cyr; Nathalie Delvoye; Liliane Meunier; Manon de Ladurantaye; Zhen Shen; Suzanna L Arcand; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson Journal: BMC Cancer Date: 2012-08-29 Impact factor: 4.430